| INTRODUCTION
There are an estimated 240 million people with chronic hepatitis B (CHB) worldwide, 1 including almost 2 million persons in the United States. 2 Due to the global obesity pandemic, the metabolic syndrome (MetS) has become a significant public health problem. 3 Dyslipidemia consisting of high triglycerides (TGL), low high-density lipoprotein cholesterol (HDL-C), and increased low-density lipoprotein cholesterol (LDL-C) and metabolic abnormalities are strongly associated with atherosclerosis and worse cardiovascular disease (CVD) outcomes. 4 The Fram-
ingham Heart study showed a strong and an independent inverse relationship among the MetS, increased levels of LDL-C, lower HDL-C, risk of CVD and all-cause mortality. [5] [6] [7] In a recent large-scale prospective study of 1466 CHB carriers, 12% of patients with comorbid metabolic syndrome had a higher cumulative probability for CV events than those without (8.0% vs 2.1%). 8 Many patients who require anti-HBV treatment receive longterm therapy with potent oral nucleos(t)ide analogues (NA) such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV) 9 TDF is also commonly used in human immunodeficiency virus (HIV) antiretroviral regimen, and studies have noted its effect on plasma lipoprotein levels in patients living with HIV. In comparison with other HIV antiretroviral therapy (ie, protease inhibitors or thymidine nucleotide analogues), TDF treatment has less mitochondrial toxicity and fewer lipodystrophy syndrome complications. 10 A pilot study by Tangsiripat et al. found that the addition of TDF to existing anti-HIV regimen lead to a significant decrease in non-HDL-C, LDL-C and total cholesterol (TC), 11 and a randomised placebo-controlled trial also showed that adding TDF/emtricitabine to darunavir/ritonavir regimen in HIVinfected patients for 12 weeks led to decreased TC and LDL-C levels compared with placebo. 12 15 In total, 853 patients were previously or currently treated for CHB of which 348 were identified for study inclusion. All study patients included were determined to be taking either TDF or ETV and had both a pre-treatment serum lipid profile and repeated lipid assessment after initiating anti-viral therapy for a minimum of 1 year.
Patients were excluded if they had received other anti-viral drugs (ie, interferon, lamivudine, adefovir, telbivudine), if they were treated for less than 1-year duration or were coinfected with HIV ( Figure 1 ). 
| Comparison of fasting lipid profile before vs after anti-viral therapy in TDF-vs ETV-treated patients
At baseline (pre-anti-viral treatment), both TDF-and ETV-treated patients had similar levels of total cholesterol, LDL-C, HDL-C and Table 2 ).
In the ETV cohort, there was no significant difference between pre-and post-treatment levels of serum lipoprotein lipids tested.
However, in the TDF-treated group, post-treatment serum lipoprotein lipids levels were significantly lower than pre-treatment levels for TC (3.92 vs 4.42, P<.01), LDL-C (2.25 vs 2.51, P<.01) and HDL-C (1.14 vs 1.34, P<.01). Triglycerides levels did not change during our study duration in the TDF group (Table 2) .
Overall, the mean difference between pre-and post-treatment lipid profile with 95% confidence interval is shown in Figure 2 . TDF- 
| TDF as an independent predictor of various levels of lipid profile change
Through propensity score matched models for age, gender, usage of lipid lowering agents, presence of comorbid dyslipidemia and diabetes mellitus, we assessed the impact of TDF compared to ETV on achieving a 20% decline on lipoprotein lipid profile components (Table 3) . Specifically, TDF-treated patients were 14% (95% CI: 3%-25%) more likely to achieve a decrease in levels of TC, 13% more likely to show a decrease in LDL-C (95% CI: 1%-25%), and 20% more likely to show a decrease in HDL (CI: 10%-30%) compared with those on ETV (Table 3) .
| DISCUSSION
In this real-life large retrospective cohort study of 348 HIV negative, CHB patients treated for a minimum of 1 year of anti-viral therapy, we compared serum lipid profiles assessed before vs after initiating either TDF or ETV treatment. In all patients, we found that similar to other published North American epidemiological studies on CHB, many are older and have significant CVS risk factors (ie, 63% male sex, 8% dyslipidemia, 11% diabetes and 13% smoking). 16 In the TDFtreated cohort, we found a significant decrease in TC and LDL-C (a primary target of lipid lowering therapies to reduce CVD risk) compared with no difference in persons who received ETV. However, there was also a concomitant significant decline in HDL-C and individuals exposed to TDF showed no significant change in TG levels.
In the setting of metabolic syndrome, lower HDL-C levels and hypertriglyceridemia are considered an independent risk factor for athero- 
